finance
S&P 500 Earnings Season Advances with 121 Companies Set to Report Q1 2026 Results Next Week
The first quarter 2026 earnings season continues, with 121 S&P 500 companies scheduled to release results next week, representing about a quarter of the index. Key reports include those from Walt Disney and McDonald's, both Dow Jones Industrial Average components, amid a focus on media, restaurants and gig economy firms. So far, 84% of reporting S&P 500 firms have exceeded earnings expectations.
May 3, 7:10 AM·3m read1 source
ai-cio.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The first quarter 2026 earnings season for the S&P 500 continues next week, with 121 companies scheduled to report results, representing approximately a quarter of the index. CNBC reported that Walt Disney and McDonald's, both in the Dow Jones Industrial Average, are among those set to release earnings. The week's reports highlight media companies, restaurant chains and gig economy platforms.
So far, 63% of S&P 500 members have issued Q1 2026 results. Of those, 84% have topped analysts' earnings expectations, according to data from FactSet. m.
ET. In Q4 2025, Palantir Technologies posted earnings that beat expectations due to strong AI and defense demand. Analysts polled by LSEG expect Palantir Technologies' Q1 2026 earnings to more than double from the year-earlier period.
Loop Capital analyst Mark Schappel wrote in a report last week that recent work, including upbeat management meetings in March, positive field checks and an expert call, points to continued AI momentum and another strong beat and raise versus estimates. Data from Bespoke Investment Group shows Palantir Technologies tops earnings estimates 90% of the time. 1% gain on earnings days.
M. ET. In Q4 2025, Pfizer reported earnings and revenue that topped analysts' estimates despite dwindling demand for its Covid products.
Analysts expect Pfizer's Q1 2026 earnings to post a double-digit decline compared with the same period a year ago, according to LSEG. The Food and Drug Administration approved Veppanu, a breast cancer drug from Pfizer and Arvinas, on Friday. Arvinas CEO Randy Teel told Reuters that the company expects more clarity on pricing for Veppanu after it announces a commercialization deal in the coming weeks.
